Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01525082
Title Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stanford University
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.